ECS14
MIMS: STENT-LESS, SIMPLE AND FAST GLAUCOMA SURGERY
Nir Israeli1,*
1Sanoculis Ltd., Kiryat Ono, Israel
Sanoculis is an Israel-based company which develops and markets the MIMS® (Minimally Invasive Micro Sclerostomy) device and surgery for the treatment of the Glaucoma. MIMS® is simple, fast, and minimally invasive requiring no stitches, eye-patch, implant or stent. It is designed to reduce the caring costs of Glaucomatous patients through simplicity, low cost, fewer post-surgical complications and less hospitalization. The CE[1]approved MIMS® surgery was launched for commercial use in Europe and Israel. Over 450 patients have undergone the MIMS® surgery with patients going through up to 3-year milestone having excellent results. Recently, Bausch + Lomb has made an equity investment in Sanoculis and has entered into an exclusive European Distribution Agreement for MIMS®. Sanoculis is currently working on two new indications (for mild and severe Glaucoma) for MIMS® which will expand its potential market to all Glaucoma patients requiring surgery. In Q4 2023, Sanoculis intends to initiate a US FDA study to obtain US regulatory approval. The MIMS® technology creates a drainage channel to reduce IOP, ensuring a long lasting safe and controlled fluid flow. During the surgery, a sclero-corneal drainage channel is created to reduce the intra-ocular pressure (IOP). The novelty of the solution is that the channel ensures long-lasting controlled fluid flow with minor complications. MIMS® consists of a disposable sterile tool and a multi-use external machine. Its benefits are: a stent-less procedure, low risk of complications, it is suitable for most Glaucoma patients, has the potential for medication reduction, can be easily combined with Cataract surgery and surgeon-friendly, automatic with short learning curve. MIMS® is designed to reduce caring costs through procedure simplicity, low cost, fewer post-surgical complications and less hospitalization.